Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05788432 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Sequent Extended Study

Study acronym: rEpic06
StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 6 months later Jun 1, 2026 → Dec 1, 2026
See other at-risk trials from Fundación EPIC

Record History

  1. Primary completion pushed from Jun 1, 2026 to Dec 1, 2026 Trial status changed: Recruiting → Active, Not Recruiting · Completion pushed from Jul 1, 2026 to Dec 1, 2026 · Enrollment target: estimated 2028 to confirmed 2040 · 1 morev24 Show 4 more changesShow less
    • Trial status changed: Recruiting → Active, Not Recruiting
    • Completion pushed from Jul 1, 2026 to Dec 1, 2026
    • Enrollment target: estimated 2028 to confirmed 2040
    • Site details revised at 27 of 27 sites
  2. Study sites: 26 to 27v23
  3. Enrollment target: 1000 to 2028v22
  4. Study sites: 25 to 26v21
  5. Primary completion date: Jun 1, 2025 to Jun 1, 2026 Completion date: Jul 1, 2025 to Jul 1, 2026v20 Show 1 more changeShow less
    • Completion date: Jul 1, 2025 to Jul 1, 2026
Show 18 earlier versionsHide 18 earlier versions
  1. Study sites: 24 to 25v19
  2. Study sites: 23 to 24v18
  3. Study sites: 22 to 23v17
  4. Study sites: 21 to 22v16
  5. Primary completion date: Dec 1, 2024 to Jun 1, 2025v15
  6. Primary completion date: Jul 1, 2024 to Dec 1, 2024v14
  7. Study sites: 20 to 21v13
  8. Study sites: 19 to 20v12
  9. Study sites: 18 to 19v11
  10. Study sites: 17 to 18v10
  11. Study sites: 16 to 17v9
  12. Study sites: 15 to 16v8
  13. Study sites: 14 to 15v7
  14. Study sites: 12 to 14v6
  15. Study sites: 9 to 12v5
  16. Study sites: 8 to 9v4
  17. Study sites: 7 to 8v3
  18. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 7 · Start date changed from estimate of Mar 30, 2023 to Mar 28, 2023v2 Show 2 more changesShow less
    • Study sites: 0 to 7
    • Start date changed from estimate of Mar 30, 2023 to Mar 28, 2023
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Multicenter, prospective, non-randomized, post-market clinical follow-up (PMCF) study to confirm and support the clinical safety and performance of Sequent Please Neo to meet EU Medical Device regulation (MDR) requirements in all the consecutive patients treated with Sequent Please Neo.
Trial Details
NCT Number NCT05788432
Lead Sponsor Fundación EPIC
Conditions Coronary Artery Disease, Ischemic Heart Disease
Enrollment 2,040 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov